tiprankstipranks
Advertisement
Advertisement

ResMed Announces CFO Transition and Confirms Growth Strategy

Story Highlights
  • Resmed CFO Brett Sandercock will retire May 4, 2026, after 27 years, shifting to an advisory role through 2027.
  • Resmed appointed former Exact Sciences CFO Aaron Bloomer as finance chief effective May 4, 2026, to support its long-term growth strategy and reaffirmed its 2026 outlook.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
ResMed Announces CFO Transition and Confirms Growth Strategy

Claim 55% Off TipRanks

Resmed ( (RMD) ) has issued an announcement.

On April 30, 2026, Resmed announced that long-serving Chief Financial Officer Brett Sandercock will retire as CFO on May 4, 2026, after 27 years at the company and 20 years in the finance chief role, and will remain a special advisor to CEO Mick Farrell through the end of 2027, signaling a managed leadership transition without internal disagreement. On the same date, the company named former Exact Sciences finance chief Aaron Bloomer as its new CFO, principal financial officer and principal accounting officer effective May 4, 2026, highlighting his track record in driving growth, margin expansion and strategic portfolio moves as Resmed reiterates its fiscal 2026 outlook and pursues its 2030 growth strategy.

The most recent analyst rating on (RMD) stock is a Buy with a $290.00 price target. To see the full list of analyst forecasts on Resmed stock, see the RMD Stock Forecast page.

Spark’s Take on RMD Stock

According to Spark, TipRanks’ AI Analyst, RMD is a Outperform.

The score is driven primarily by strong financial performance (high margins, low leverage, and robust free cash flow) and a favorable earnings call emphasizing margin progress, clear FY26 operating targets, and substantial capital returns. Offsetting factors are a premium valuation (P/E ~26) with a low yield and only moderate technical momentum.

To see Spark’s full report on RMD stock, click here.

More about Resmed

Resmed Inc. is a leading health technology company focused on sleep, breathing and home-based care, with AI-powered digital health solutions, cloud-connected devices and intelligent software deployed in 140 countries. Its products and platforms aim to make home healthcare more personalized, accessible and effective, supporting a vision that better sleep and breathing help people achieve their full potential.

Average Trading Volume: 1,096,259

Technical Sentiment Signal: Sell

Current Market Cap: $30.87B

See more insights into RMD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1